Aclaris Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Aclaris Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.68M | Mar 12, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.83M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $18.72M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $31.25M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $29.75M | Feb 27, 2024 |
| FY2023 | Dec 31, 2021 | $6.76M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $6.48M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $4.23M | Feb 24, 2022 |
| FY2018 | Dec 31, 2018 | $3.67M | Mar 18, 2019 |
| FY2018 | Sep 30, 2018 | $1.63M | Mar 18, 2019 |
| FY2018 | Jun 30, 2018 | $3.68M | Mar 18, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $999.0K | Mar 12, 2018 |
| FY2017 | Sep 30, 2017 | $684.0K | Mar 12, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $160.0K | Mar 18, 2019 |
| FY2018 | Sep 30, 2018 | $435.0K | Mar 18, 2019 |
| FY2018 | Jun 30, 2018 | $2.50M | Mar 18, 2019 |
| FY2018 | Mar 31, 2018 | $151.0K | Mar 18, 2019 |
| FY2018 | Dec 31, 2017 | $245.0K | Mar 18, 2019 |
| FY2018 | Sep 30, 2017 | $231.0K | Mar 18, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($64.92M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($132.07M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($88.48M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($86.91M) | Feb 27, 2024 |
| FY2023 | Dec 31, 2021 | ($90.87M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($51.02M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | ($161.35M) | Feb 24, 2022 |
| FY2018 | Dec 31, 2018 | ($38.55M) | Mar 18, 2019 |
| FY2018 | Sep 30, 2018 | ($32.74M) | Mar 18, 2019 |
| FY2018 | Jun 30, 2018 | ($31.22M) | Mar 18, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($76.38M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($141.93M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($97.36M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($89.85M) | Feb 27, 2024 |
| FY2023 | Dec 31, 2021 | ($89.72M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($50.91M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | ($111.06M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($84.78M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($54.36M) | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | ($48.57M) | Mar 18, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.65M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $33.59M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $98.38M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $77.81M | Feb 27, 2024 |
| FY2023 | Dec 31, 2021 | $43.81M | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $29.34M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $64.17M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $60.84M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $35.80M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $33.48M | Mar 18, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($47.11M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($20.08M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($78.33M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($67.57M) | Feb 27, 2024 |
| FY2023 | Dec 31, 2021 | ($52.13M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | ($38.63M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | ($96.45M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($100.81M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | ($54.66M) | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | ($34.60M) | Mar 18, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $111.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $121.0K | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.31M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $605.0K | Feb 27, 2024 |
| FY2023 | Dec 31, 2021 | $308.0K | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | $453.0K | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $1.61M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $1.36M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $1.24M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $232.0K | Mar 18, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $160.46M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $220.33M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $197.41M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $254.60M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $251.21M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $70.78M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $98.30M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $275.57M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $243.51M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $176.09M | Mar 12, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.38M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $64.77M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $40.23M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $56.98M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $53.87M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $33.13M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $28.39M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $60.44M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $18.25M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $6.60M | Mar 12, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.08M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $155.55M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $157.18M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $197.62M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $197.34M | Feb 27, 2024 |
| FY2023 | Dec 31, 2020 | $37.65M | Feb 27, 2024 |
| FY2022 | Dec 31, 2019 | $69.91M | Feb 23, 2023 |
| FY2021 | Dec 31, 2018 | $215.12M | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | $225.26M | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $169.49M | Feb 25, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2018 | $18.50M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $18.50M | Mar 18, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($967.78M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($902.86M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($770.80M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($682.32M) | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | ($595.41M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($504.54M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($453.53M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($292.17M) | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | ($159.44M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($90.91M) | Mar 12, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.96M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $24.57M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $39.88M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $45.28M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | $27.35M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $22.06M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $34.19M | Feb 25, 2021 |
| FY2017 | Dec 31, 2017 | $20.20M | Mar 12, 2018 |
| FY2017 | Dec 31, 2016 | $30.17M | Mar 12, 2018 |
| FY2017 | Dec 31, 2015 | $9.85M | Mar 12, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | $10.65M | Feb 24, 2022 |
| FY2019 | Dec 31, 2018 | $29.91M | Feb 25, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Feb 27, 2024 |
| FY2023 | Dec 31, 2021 | (1) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | (3) | Feb 24, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Feb 27, 2024 |
| FY2023 | Dec 31, 2021 | (1) | Feb 27, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | (3) | Feb 24, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 120.50M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 107.85M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 70.89M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 66.69M | Feb 27, 2024 |
| FY2022 | Dec 31, 2021 | 61.23M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | 45.11M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 41.49M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 41.21M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | 30.86M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | 26.06M | Mar 12, 2018 |